Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17541115 | 0.83 | CA12 (0.50) | CHRNB4CHRNA3CHRNA7MRGPRX4MAOB | |
| SCHEMBL827016 | 0.83 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNA7MRGPRX4MAOB | |
| SCHEMBL3541660 | 0.83 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNA7MRGPRX4MAOB | |
| SCHEMBL14359475 | 0.79 | KCNA3 (0.48) | MRGPRX4MAOBMAOASIGMAR1CA2 | |
| SCHEMBL17541039 | 0.79 | KDM4E (0.51) | CHRNB4CHRNA3CHRNA7MRGPRX4MAOB | |
| SCHEMBL27767737 | 0.79 | MAOB (0.68) | MAOBMAOASIGMAR1ACHEBCHE | |
| SCHEMBL7693072 | 0.79 | MRGPRX4 (0.50) | CHRNB4CHRNA3CHRNA7MRGPRX4MAOB | |
| SCHEMBL3791638 | 0.79 | CA2 (0.51) | CHRNB4CHRNA3CHRNA7MRGPRX4CA2 | |
| SCHEMBL28618849 | 0.79 | MRGPRX4 (0.49) | CHRNB4CHRNA3CHRNA7MRGPRX4MAOB | |
| SCHEMBL17338661 | 0.78 | MAOA (0.67) | CHRNB4CHRNA3CHRNA7MRGPRX4MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029543-B1 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH LLC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-7781591-B2 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC (US) | 2010-08-24 | — | — | US | disclosed |
| EP-2029543-A2 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007146376-A2 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K7 | CHRNB4 2213/4885CHRNA3 1106/4885CHRNA7 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.